Part 4/8:
The interview illuminated the complex reasons behind the limited availability of medications for addiction treatment compared to other medical fields, like hypertension. It’s not a lack of scientific understanding; rather, the pharmaceutical industry exhibits a general disinterest in developing addiction treatment medications. This disinterest stems from various factors, including societal stigma surrounding addiction, economic disincentives for healthcare providers, and bureaucratic hurdles in obtaining medication approval from the FDA.